KYN-5356 is under clinical development by Kynexis Therapeutics and currently in Phase I for Cognitive Impairment Associated With Schizophrenia (CIAS). According to GlobalData, Phase I drugs for Cognitive Impairment Associated With Schizophrenia (CIAS) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the KYN-5356 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Kynexis Therapeutics overview
Kynexis Therapeutics, a subsidiary of KyNexis BV, is a biotechnology company engaged in research and development of precision therapeutics for treatment of brain diseases. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of KYN-5356’s drug-specific PTSR and LoA scores, buy the report here.